BioNTech raises $270 million for cancer vaccines

BioNTech AG, Europe’s largest privately-held biotech company, has raised $270 million in a Series A financing round to advance a portfolio of oncology drugs tailored to individual cancers. The round was led by the Redmile Group and joined by the Struengmann Family Office, a founding investor.

Full text available to subscribers only. Click here for information on subscribing to MedNous.